Log in

Relevant bibliographies by topics / Allerona / Journal articles

Journal articles on the topic 'Allerona'

To see the other types of publications on this topic, follow the link: Allerona.

Author: Grafiati

Published: 9 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Allerona.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Baldanza, Angela, Roberto Bizzarri, Chiara Boschi, Federico Famiani, Francesco Frondini, Marco Lezzerini, Steven Rowland, and Paul A. Sutton. "CO2-Degassing Carbonate Conduits in Early Pleistocene Marine Clayey Deposits in Southwestern Umbria (Central Italy)." Minerals 12, no. 7 (June 27, 2022): 819. http://dx.doi.org/10.3390/min12070819.

Full text

Abstract:

Early Pleistocene marine deposits in southwestern Umbria (Orvieto–Allerona area, Italy) recently revealed the presence of more than forty carbonate conduits distributed over 2 km along the Paglia riverbed. In order to investigate their origins, analyses of their mineralogy, δ18O and δ13C stable isotopes, and organic geochemistry were conducted. All the carbonate conduits are made of euhedral microcrystals of dolomite with subordinate quartz, plagioclases, and micas. The stable carbon and oxygen isotope values of the bulk concretionary carbonates range from −0.57 to +4.79‰ (δ13C) and from +1.58 to +4.07‰ (δ18O), respectively. The lack of organic geochemical biomarkers of anaerobic methane oxidation (AOM) and the very low values of extractable organic matter suggest a non-biological origin for the dolomite precipitation. The latter is probably related to the rise of volcanic carbon dioxide due to the incipient Vulsini magmatism recorded in Early Pleistocene marine deposits all around the study site. The spatial distribution of the structures indicates that the upward migration of the CO2 was controlled by the fault system, while the vertical development of the conduits suggests that carbon dioxide degassing occurred, with multiple events. Carbon dioxide was probably stored in pockets within the clayey sediments until the pressure exceeded the eruptive threshold. These structures represent the first documentation of a volcanic carbon dioxide marine seepage event in the Umbria region.

APA, Harvard, Vancouver, ISO, and other styles

2

Syrett, Nicholas L. "“Lord of a Hawaiian Island”." Pacific Historical Review 82, no. 3 (November 2012): 396–427. http://dx.doi.org/10.1525/phr.2013.82.3.396.

Full text

Abstract:

This case study of a white male couple (Robert and John Gregg Allerton) on Kaua‘i from the 1930s through the 1960s investigates how their colonization of the island has tended to be erased in accounts that highlight both the supposed acceptance of their homosexuality by the island’s residents and, in turn, the couple’s generous philanthropy. Set against this narrative of what Mary Louise Pratt has called “anti-conquest,” I demonstrate that the Allertons’ lives on Kaua‘i were actually more in keeping with the history of western imperialism than most accounts acknowledge, emphasizing also their own innovative strategies toward making the island their own. The article examines both the specifics of the Allertons’ colonizing of Kaua‘i and, more importantly, how imperialism can be misremembered when the colonizers were queer, connecting that narrative obfuscation to myths about acceptance of gay men in Hawai‘i that live on today.

APA, Harvard, Vancouver, ISO, and other styles

3

Brais, Hadi, and Preeti Ranjan Panda. "Alleria." ACM Transactions on Embedded Computing Systems 18, no. 5s (October 19, 2019): 1–22. http://dx.doi.org/10.1145/3358193.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

&NA;. "Cyclosporin ??? Allergan." Drugs in R & D 4, no. 2 (2003): 126–27. http://dx.doi.org/10.2165/00126839-200304020-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Jarlot, S., M. Hosotte, D. Dano, and G. Kanny. "Allergia alimentare." EMC - AKOS - Trattato di Medicina 16, no. 1 (March 2014): 1–6. http://dx.doi.org/10.1016/s1634-7358(14)66965-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Anonymous. "Allergan Disinfection System." Journal of Refractive Surgery 3, no. 3 (May 1987): 109. http://dx.doi.org/10.3928/1081-597x-19870501-11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

SK. "Allergan startet Qualitätsinitiative." ästhetische dermatologie & kosmetologie 4, no. 3 (June 2012): 24. http://dx.doi.org/10.1007/s12634-012-0306-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

&NA;. "Botulinum Toxin A (Allergan)." Drugs in R & D 2, no. 6 (February 1999): 381–82. http://dx.doi.org/10.2165/00126839-199902060-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Anonymous. "Allergan Introduces New Steroid." Journal of Refractive Surgery 2, no. 5 (September 1986): 236. http://dx.doi.org/10.3928/1081-597x-19860901-15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Mandavilli, Apoorva. "Profile: Dominique Toran-Allerand." Nature Medicine 11, no. 10 (September 28, 2005): 1022. http://dx.doi.org/10.1038/nm1005-1022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

&NA;, &NA;. "Pyott to Pilot Allergan." Optometry and Vision Science 75, no. 1 (January 1998): 4. http://dx.doi.org/10.1097/00006324-199801000-00011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Hamernik, Debora L., Harris A. Lewin, and Lawrence B. Schook. "Allerton III. Beyond Livestock Genomics." Animal Biotechnology 14, no. 1 (June 2003): 77–82. http://dx.doi.org/10.1081/abio-120022137.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

&NA;, &NA;. "Allergan Reports 1996 Operating Results." Optometry and Vision Science 74, no. 2 (February 1997): 73. http://dx.doi.org/10.1097/00006324-199702000-00015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

&NA;, &NA;. "Allergan Reports First Quarter Results." Optometry and Vision Science 74, no. 6 (June 1997): 343. http://dx.doi.org/10.1097/00006324-199706000-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

&NA;, &NA;. "Allergan IOL Receives FDA OK." Optometry and Vision Science 74, no. 9 (September 1997): 696. http://dx.doi.org/10.1097/00006324-199709000-00011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

&NA;, &NA;. "Allergan Deals Paremyd to Akorn." Optometry and Vision Science 75, no. 4 (April 1998): 240. http://dx.doi.org/10.1097/00006324-199804000-00012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Levantino, Laura, Cristiana Corrado, Laura Badina, Sara Lega, and Egidio Barbi. "Ipersensibilità ai FANS: intolleranza o allergia?" Medico e Bambino 40, no. 1 (January 28, 2021): 37–43. http://dx.doi.org/10.53126/meb40037.

Full text

Abstract:

Non-steroidal anti-inflammatory drugs (NSAIDs) are the main triggers of drug hypersensitivity reactions in children. According to the EAACI latest classification NSAIDs hypersensitivity reactions are differentiated into cross-reactive reactions, with non-immunological mechanisms (based on COX-1 inhibition), and selective reactions, with immunological mechanisms. Paediatric clinical manifestations of NSAID hypersensitivity are typically cutaneous, but sometimes, similarly to anaphylaxis, can involve other systems, especially the respiratory one. Differentiating between NSAID intolerance and NSAID allergy through drug provocation tests is crucial for the patient because the two clinical entities require different management.

APA, Harvard, Vancouver, ISO, and other styles

18

Lendvai-Emmert, Dominika, Vanessza Emmert, Katalin Fusz, Viktória Prémusz, Viktória Németh, Roland Ligetvári, and Gergely Péter Tóth. "A gyermekkori tehéntejfehérje-allergia diagnosztikai kihívásai." Orvosi Hetilap 160, no. 33 (August 2019): 1311–18. http://dx.doi.org/10.1556/650.2019.31458.

Full text

Abstract:

Abstract: Introduction and aim: The aim of our research is to evaluate and compare commonly performed diagnostic tests, and to examine the psychological disorders induced by this food allergy. Children with symptoms suggesting cow’s milk protein allergy were included in this study (n = 47). Blood and saliva samples were collected from the participants. Parents were asked to fill in a questionnaire constructed by the research team (containing the DSM-5 symptoms checklist about attention deficit hyperactivity disorder). Method: One of the most widely used diagnostic tool is the skin allergy test, which was performed in 47 subjects (n = 47, mean age: 7.36 years); only 2 children showed positive test result for cow’s milk. Lymphocyte transformation test was observed to be positive in 8 children (17%), 4 subjects demonstrated questionable results. In our sub-study about psychological symptoms (n = 43, mean age: 7.88 years), the score was according to the attention deficit hyperactivity disorder symptom checklist before the diet (6.88, SD: 4.43) and showed significant decrease after 3 months of the elimination diet (4.48, SD: 3.69, p = 0.001). Scores of children with sleep disorder (10.62, SD: 4.23) also represented a significant reduction after 3 months of the diet (6.69, SD: 4.59, p = 0.009). Salivary cortisol levels did not show significant changes before and after elimination diet. Results: According to our data, skin allergy testing and lymphocyte transformation test are not reliable diagnostic tools for establishing the diagnosis. Conclusion: We conclude that a significant improvement in clinical symptoms can only be achieved with a strict elimination diet. Orv Hetil. 2019; 160(33): 1311–1318.

APA, Harvard, Vancouver, ISO, and other styles

19

MALTMAN, J. "Perspectives for new treatments at Allergan." Acta Ophthalmologica 90 (August 6, 2012): 0. http://dx.doi.org/10.1111/j.1755-3768.2012.2823.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

&NA;, &NA;. "Allergan??s Acular Receives Additional Indication." Optometry and Vision Science 74, no. 1 (January 1997): 6. http://dx.doi.org/10.1097/00006324-199701000-00012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

&NA;, &NA;. "Allergan Expects Lower First Half Earnings." Optometry and Vision Science 74, no. 4 (April 1997): 178. http://dx.doi.org/10.1097/00006324-199704000-00017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

&NA;. "Allergan Reviews R&D Progress." Optometry and Vision Science 74, no. 5 (May 1997): 243. http://dx.doi.org/10.1097/00006324-199705000-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

&NA;. "Allergan Continues to Expand Research Efforts." Optometry and Vision Science 74, no. 12 (December 1997): 980. http://dx.doi.org/10.1097/00006324-199712000-00012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

&NA;, &NA;. "Allergan Markets New Preservative-Free NSAID." Optometry and Vision Science 75, no. 3 (March 1998): 164. http://dx.doi.org/10.1097/00006324-199803000-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

&NA;, &NA;. "Allergan Sales Drop 1% for 1997." Optometry and Vision Science 75, no. 4 (April 1998): 241. http://dx.doi.org/10.1097/00006324-199804000-00015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Vörös, Krisztina, János Bobvos, Mihály János Varró, Tibor Málnási, Tamás Kói, Donát Magyar, Péter Rudnai, and Anna Páldy. "A hosszú távú pollenterhelés és légszennyezettség hatásának vizsgálata a parlagfűpollen-allergia előfordulási gyakori-ságával összefüggésben." Egészségtudomány 62, no. 1-2 (2018): 58–84. http://dx.doi.org/10.29179/egtud.2018.1-2.58.

Full text

Abstract:

Bevezetés: Azt tűztük ki célul, hogy elemezzük az összefüggést a hazánkban jelentős népegészségügyi problémának számító parlagfűpollen-allergia előfordulási gyakorisága és a hosszú távú pollenterhelés, valamint egyes légszennyezők (NO2, PM10, CO) hatása, továbbá egyes kora gyermekkori környezeti tényezők között. Módszerek: A vizsgálathoz az Országos Közegészségügyi Központ által végzett országos szintű, az ISAAC tanulmány kérdőívén alapuló felmérés (Országos Gyermek Légúti Felmérés, OGYELF, 2005) parlagfűallergiára és lehetséges kockázati tényezőire vonatkozó kérdéseit használtuk fel. A települések hosszú távú pollenexpozícióját az országot lefedő 19 aerobiológiai mérőállomás átlagos napi pollenkoncentrációiból számoltuk, míg a hosszú távú légszennyezettséget kormányrendelet alapján kialakított légszennyezettségi zónákba sorolás alapján kaptuk. Az elemzéshez leíró és analitikus statisztikai módszereket alkalmaztunk. Eredmények: A mérések alapján jellemző magas tartományban a pollenterhelés nem mutatott szignifikáns összefüggést az allergia rizikójával. Országos szinten szignifikánsan kisebb volt az allergia előfordulása az alacsonyabb légszennyezettségű területeken, Pest megye kizárása után azonban ez a szignifikáns hatás eltűnt. Gyakrabban fordult elő allergia fiú gyermekeknél, továbbá növelte az allergia rizikóját a pozitív családi anamnézis, a kora gyermekkori súlyos, alsó légúti infekció, a különálló, saját gyermekszoba. A rendszeres szociális juttatásban részesülő szülők gyermekeinél kisebb gyakorisággal fordult elő allergia. A várandósság alatti dohányzás negatív összefüggést mutatott a kimenetellel az országos elemzésben, de Pest megye kizárásával a szignifikancia eltűnt. Az anyai életkor a gyermek születésekor nem mutatott szignifikáns összefüggést az allergiarizikóval. Következtetés: A genetikai hajlam mellett számos környezetei tényező is szerepet játszik a fokozott allergiarizikó hátterében, ugyanakkor az előfordulási gyakoriságot egyéb faktorok (szülői ismeretek az allergia tüneteiről, infrastrukturális különbségek, ellátórendszerhez való hozzáférhetőség) is befolyásolhatják, melyek hatását további vizsgálatokban tervezzük elemezni.

APA, Harvard, Vancouver, ISO, and other styles

27

Fábos, Beáta, and Zita Battyáni. "A PPD allergia jelentôsége a mindennapi gyakorlatban." Bőrgyógyászati és Venerológiai Szemle 90, no. 1 (February 28, 2014): 11–16. http://dx.doi.org/10.7188/bvsz.2014.90.1.2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Endre, László. "Új, epicutan módszer az allergia oki kezelésére." Orvosi Hetilap 158, no. 23 (June 2017): 895–99. http://dx.doi.org/10.1556/650.2017.30762.

Full text

Abstract:

Abstract: The only causal treatment for the allergic diseases is the allergen immunotherapy. Besides oral and injection forms, an epicutaneous form is known as well. During the immunization process the use of an adjuvant material is advisable besides the allergen. That adjuvant material can be (besides of the aluminium hydroxid and tyrosine) a bacterial toxin, too. In idealistic circumstances we can substitute the native allergen with its recombinant variant, which could keep its immunogenicity but had lost the allergenicity. In the future the recommended therapy could be the safe, painless, epicutaneous hyposensitization, with recombinant allergens, with bacterial toxin as adjuvants. Orv Hetil. 2017; 158(23): 895–899.

APA, Harvard, Vancouver, ISO, and other styles

29

Mogee, Mary Ellen, and Richard G. Kolar. "Patent citation analysis of Allergan pharmaceutical patents." Expert Opinion on Therapeutic Patents 8, no. 10 (October 1998): 1323–46. http://dx.doi.org/10.1517/13543776.8.10.1323.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

&NA;, &NA;. "Allergan???s Business Model is Now History." Optometry and Vision Science 76, no. 7 (July 1999): 438. http://dx.doi.org/10.1097/00006324-199907000-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

&NA;, &NA;. "Allergan Research Develops Highly Selective Receptor Agonists." Optometry and Vision Science 76, no. 10 (October 1999): 671–72. http://dx.doi.org/10.1097/00006324-199910000-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Unger, Jacob G., Jennel M. Carreras, Purushottam Nagarkar, Haneol S. Jeong, and William Carpenter. "Allergan Style 410 Implants for Breast Reconstruction." Plastic and Reconstructive Surgery 138, no. 3 (September 2016): 548–55. http://dx.doi.org/10.1097/prs.0000000000002429.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Wright, Lesley. "Ligand and Allergan form $100 million venture." Nature Biotechnology 13, no. 2 (February 1995): 107. http://dx.doi.org/10.1038/nbt0295-107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Risser, Paul G. "The Allerton Park workshop revisited ? A commentary." Landscape Ecology 10, no. 3 (June 1995): 129–32. http://dx.doi.org/10.1007/bf00133026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Réthy Lajos, Lajos Attila. "A csecsemőkori allergia-megelőzés korszerű irányelvei és lehetőségei." Egészségfejlesztés 58, no. 1 (2017): 49–54. http://dx.doi.org/10.24365/ef.v58i1.134.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Németh, Dominik. "Kontakt allergia vizsgálata Magyarországon az elmúlt 100 évben." Kaleidoscope history 11, no. 23 (2021): 328–38. http://dx.doi.org/10.17107/kh.2021.23.328-338.

Full text

Abstract:

The diagnostic method used for detecting contact sensitization is the patch test. The development of the methodology of this procedure has a long history. Selection of the patch test materials, their concentrations and vehicles, the occlusion time and reading time were also determined. This development is a result of the activities of outstanding dermatologists and allergologists of the past 100 years.

APA, Harvard, Vancouver, ISO, and other styles

37

Németh, Dominik. "Kontakt allergia vizsgálata Magyarországon az elmúlt 100 évben." Kaleidoscope history 11, no. 23 (2021): 328–39. http://dx.doi.org/10.17107/kh.2021.23.328-339.

Full text

Abstract:

The diagnostic method used for detecting contact sensitization is the patch test. The development of the methodology of this procedure has a long history. Selection of the patch test materials, their concentrations and vehicles, the occlusion time and reading time were also determined. This development is a result of the activities of outstanding dermatologists and allergologists of the past 100 years.

APA, Harvard, Vancouver, ISO, and other styles

38

&NA;, &NA;. "Allergan Reaches Agreement for Aggressive Marketing of Ocuflox." Optometry and Vision Science 76, no. 12 (December 1999): 809. http://dx.doi.org/10.1097/00006324-199912000-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

AULT, ALICIA. "Allergan Fined For Off-Label Push of Botox." Family Practice News 40, no. 15 (September 2010): 6. http://dx.doi.org/10.1016/s0300-7073(10)70927-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Han, Sang B., Chang W. Lee, Song K. Park, Won K. Yoon, Jae S. Moon, Ki H. Lee, Hyung C. Kim, and Hwan M. Kim. "Prevention of macrophage-related inflammatory diseases by allergina." Archives of Pharmacal Research 26, no. 4 (April 2003): 312–16. http://dx.doi.org/10.1007/bf02976961.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Jeong, Hyun-Ja, Hwan-Suck Chung, Hyo-Jin An, Joon-Bae Kim, Eun-Mi Lee, Eun-Jeong Park, Chul-Ho Jang, Seung-Heon Hong, and Hyung-Min Kim. "Immune-enhancement effect of the herbal combination Allergina." Clinica Chimica Acta 337, no. 1-2 (November 2003): 77–84. http://dx.doi.org/10.1016/j.cccn.2003.07.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Castanheira, Mariana, Timothy B. Doyle, Cory Hubler, Rodrigo E. Mendes, and Helio S. Sader. "1443. Activity of Ceftazidime-Avibactam against Carbapemenase-negative Carbapenem-resistant Enterobacterales (CRE) Isolates from US Hospitals." Open Forum Infectious Diseases 7, Supplement_1 (October 1, 2020): S725. http://dx.doi.org/10.1093/ofid/ofaa439.1624.

Full text

Abstract:

Abstract Background Most CRE isolates in US hospitals produce KPC enzymes, but some do not carry carbapenemases. We investigated the prevalence, resistance mechanisms and activity of ceftazidime-avibactam and comparator agents against CRE that did not carry carbapenemase genes from US hospitals. Additionally, meropenem-resistant isolates were tested for meropenem-vaborbactam. Methods A total of 28,904 Enterobacterales isolates were collected in 70 US hospitals during 2016-2018, and susceptibility tested by reference broth microdilution. Meropenem-vaborbactam was tested using lyophilized panels following the manufacturer’s instructions. CRE isolates were submitted to whole genome sequencing for the screening of b-lactamase genes, multilocus sequence typing, changes in outer membrane protein (OMP) genes and AmpC expression levels. Results A total of 304 (1.1%) CREs were observed in the study period and 45 (14.8%) isolates did not carry carbapenemases. These isolates were mainly Klebsiella aerogenes, Enterobacter cloacae and Klebsiella pneumoniae (11, 11 and 10 isolates, respectively), but also included 5 other species. Acquired b-lactamase genes were detected among 17 isolates and blaCTX-M-15 was the most common (13 isolates). All K. aerogenes and 10 E. cloacae did not carry acquired b-lactamase genes. Ceftazidime-avibactam (100% susceptible) inhibited all isolates at the current breakpoint, followed by tigecycline and amikacin (> 80% susceptible). Other comparators were not active against non-carbapenemase-producing CRE. Nine of 35 meropenem-resistant isolates displayed meropenem-vaborbactam MIC values of ≥ 8 mg/L (nonsusceptible). Further analysis showed that 23 isolates had disruption of OmpC/OmpK36, 4 had disrupted OmpF/OmpK35 and 13 had both OMP genes disrupted. Additionally, 7 isolates had elevated AmpC expression among 17 isolates tested. Among 7 E. coli, 4 were ST131 and only 2 of 10 K. pneumoniae were clonal complex 11. Conclusion Therapy options for treatment of infections caused by CRE were very limited until recent approval of new agents with activity against these isolates. Ceftazidime-avibactam demonstrated full in vitro activity against all carbapenemase-negative CRE carrying multiple resistance mechanisms. Disclosures Mariana Castanheira, PhD, 1928 Diagnostics (Research Grant or Support)A. Menarini Industrie Farmaceutiche Riunite S.R.L. (Research Grant or Support)Allergan (Research Grant or Support)Allergan (Research Grant or Support)Amplyx Pharmaceuticals (Research Grant or Support)Cidara Therapeutics (Research Grant or Support)Cidara Therapeutics (Research Grant or Support)Cipla Ltd. (Research Grant or Support)Cipla Ltd. (Research Grant or Support)Fox Chase Chemical Diversity Center (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Merck (Research Grant or Support)Merck (Research Grant or Support)Merck & Co, Inc. (Research Grant or Support)Merck & Co, Inc. (Research Grant or Support)Paratek Pharma, LLC (Research Grant or Support)Pfizer (Research Grant or Support)Qpex Biopharma (Research Grant or Support) Timothy B. Doyle, Allergan (Research Grant or Support)Allergan (Research Grant or Support)Cipla Ltd. (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Pfizer (Research Grant or Support)Qpex Biopharma (Research Grant or Support) Cory Hubler, Allergan (Research Grant or Support) Rodrigo E. Mendes, PhD, A. Menarini Industrie Farmaceutiche Riunite S.R.L. (Research Grant or Support)Allergan (Research Grant or Support)Allergan (Research Grant or Support)Basilea Pharmaceutica International, Ltd (Research Grant or Support)Cipla Ltd. (Research Grant or Support)Department of Health and Human Services (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Merck (Research Grant or Support)Merck (Research Grant or Support)Pfizer (Research Grant or Support) Helio S. Sader, MD, PhD, A. Menarini Industrie Farmaceutiche Riunite S.R.L. (Research Grant or Support)Allergan (Research Grant or Support)Allergan (Research Grant or Support)Allergan (Research Grant or Support)Cipla Ltd. (Research Grant or Support)Cipla Ltd. (Research Grant or Support)Melinta (Research Grant or Support)Merck (Research Grant or Support)Merck (Research Grant or Support)Paratek Pharma, LLC (Research Grant or Support)Pfizer (Research Grant or Support)

APA, Harvard, Vancouver, ISO, and other styles

43

Longo, Giorgio. "Domande e risposte." Medico e Bambino 39, no. 10 (December 15, 2020): 665. http://dx.doi.org/10.53126/meb39665.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Nowak, Michael, Urania Rappo, Pedro L. Gonzalez, Jie Chen, Jennifer S. McGregor, Jason Bryowsky, and David Talan. "Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Patients with Diabetes Mellitus." Open Forum Infectious Diseases 4, suppl_1 (2017): S95. http://dx.doi.org/10.1093/ofid/ofx163.068.

Full text

Abstract:

Abstract Background ABSSSIs are common in patients with diabetes and have an increased risk of complications. Dalbavancin is a long-acting lipoglycopeptide with potent activity against Gram-positive pathogens responsible for ABSSSI, including methicillin-resistant Staphylococcus aureus (MRSA), and has demonstrated activity in ABSSSI with single-dose administration. We assessed outcomes in patients with and without diabetes in a clinical trial evaluating the efficacy of dalbavancin for ABSSSI. Methods In a double-blind, phase 3 trial, adult patients with ABSSSI involving deeper soft tissue or requiring significant surgical intervention, defined as major abscess, cellulitis, and traumatic wound/surgical site infection were randomized 1:1 to dalbavancin as a single-dose (1500 mg) or as a two-dose regimen (1000 mg on Day 1 and 500 mg on Day 8). The primary endpoint was ≥20% reduction in erythema at 48–72 hours; clinical success on Days 14 and 28 was defined as improvement in lesion size and signs and symptoms. P-values were obtained using Fisher’s exact test for categorical variables and Wilcoxon rank-sum test for continuous variables. In a post-hoc subgroup analysis, outcomes were compared among the subgroups of participants with and without diabetes. Results There were 76/698 (10.9%) participants with diabetes and 622/698 (89.1%) participants without diabetes. Participants with diabetes were more likely to be older or obese, and had higher rates of cellulitis, while participants without diabetes had higher rates of abscess (Figure 1). At Days 14 and 28, clinical success was achieved in ≥84% of participants with diabetes, and investigator assessment of cure was achieved in ≥95% of participants with diabetes (Figure 2). Drug-related adverse events were observed in 7 (9.2%) patients with and 44 (7.1%) participants without diabetes. Conclusion Dalbavancin has similar rates of clinical response and success for the treatment of ABSSSI in patients with or without diabetes. Disclosures M. Nowak, Allergan plc: Employee, Salary. U. Rappo, Allergan plc: Employee and Shareholder, Salary. P. L. Gonzalez, Allergan plc: Employee and Shareholder, Salary. J. Chen, Allergan plc: Employee, Salary. J. S. McGregor, Allergan plc: Employee, Salary. J. Bryowsky, Allergan plc: Employee and Shareholder, Salary.

APA, Harvard, Vancouver, ISO, and other styles

45

Schneider, Katie H., Lisa T. Goberdhan, Elizabeth T. Makino, and Rahul C. Mehta. "Combining In-Office Chemical Peel Procedures with Topical Therapy of a Comprehensive Pigmentation Control Product for Multi-Ethnic Subjects with Moderate-to-Severe Facial Hyperpigmentation." SKIN The Journal of Cutaneous Medicine 1 (October 27, 2017): s101. http://dx.doi.org/10.25251/skin.1.supp.100.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Makino, Elizabeth, Priscilla Tan, and Rahul C. Mehta. "Clinical Efficacy and Tolerability of a Cosmetic Growth Factor Serum for Overall Facial Photodamage." SKIN The Journal of Cutaneous Medicine 1 (October 27, 2017): s64. http://dx.doi.org/10.25251/skin.1.supp.63.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Fagien, Steve, Joel Cohen, William Coleman, Gary Monheit, Jean Caruthers, Cheri Mao, Domenico Vitarella, Xiaofang Lei, and Bhushan Hardas. "Efficacy and Safety of OnabotulinumtoxinA for Treatment of Moderate-to-Severe Forehead Lines." SKIN The Journal of Cutaneous Medicine 1 (October 27, 2017): s72. http://dx.doi.org/10.25251/skin.1.supp.71.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

De Boulle, Koen, Philip Werschler, Michael H. Gold, Gerhard Sattler, Patricia Ogilvie, Cheri Mao, Domenico Vitarella, Xiaofang Lei, and Bhushan Hardas. "Efficacy and Safety of OnabotulinumtoxinA for Moderate-to-Severe Forehead Lines in Subjects with Upper Facial Lines." SKIN The Journal of Cutaneous Medicine 1 (October 27, 2017): s73. http://dx.doi.org/10.25251/skin.1.supp.72.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Makino, Elizabeth T., Priscilla Tan, and Rahul Mehta. "Immediate and Long-Term Efficacy of a Two-Step Topical Hyaluronic Acid Lip Treatment." SKIN The Journal of Cutaneous Medicine 1 (October 27, 2017): s76. http://dx.doi.org/10.25251/skin.1.supp.75.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Monheit, Gary, Pearl E. Grimes, Bhushan Hardas, Vince Lin, and Diane K. Murphy. "Juvederm Vollure XC is Safe and Effective for Correcting Nasolabial Folds: Results from a Randomized Controlled Study." SKIN The Journal of Cutaneous Medicine 1 (October 27, 2017): s77. http://dx.doi.org/10.25251/skin.1.supp.76.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!